Vertex Pharmaceuticals (VRTX) Non-Current Deffered Revenue (2009 - 2017)

Vertex Pharmaceuticals' Non-Current Deffered Revenue history runs 9 years deep, the most recent figure standing at $1.7 million for Q4 2017.

• On a quarterly basis, Non-Current Deffered Revenue fell 73.97% year-over-year to $1.7 million in Q4 2017; TTM through Dec 2017 was $1.7 million, a 73.97% decrease from a year earlier, with the FY2017 full-year figure at $1.7 million, down 73.97% from the prior year.
• Non-Current Deffered Revenue slipped to $1.7 million in Q4 2017 per VRTX's latest filing, from $2.9 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $90.3 million in Q1 2013 and bottomed at $1.7 million in Q4 2017.
• The 5-year median for Non-Current Deffered Revenue is $19.3 million (2015), against an average of $28.1 million.
• Across the five-year window, Non-Current Deffered Revenue declined 22.28% in 2013 and slumped 73.97% in 2017, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $49.5 million in 2013, then tumbled by 43.78% to $27.8 million in 2014, then slumped by 65.07% to $9.7 million in 2015, then sank by 31.73% to $6.6 million in 2016, then plunged by 73.97% to $1.7 million in 2017.
• Per Business Quant, the three latest VRTX Non-Current Deffered Revenue figures stand at $1.7 million (Q4 2017), $2.9 million (Q3 2017), and $4.2 million (Q2 2017).